Emerging Stock Report Initiates Independent Research Coverage on Nutra Pharma Corp.

Emerging Stock Report, a leading provider of sector specific independent investment research, today initiated coverage on Nutra Pharma Corp. (OTCBB:NPHC) Emerging Stock Report is currently offering a complimentary trial subscription. To view our research go to www.emergingstockreport.com.

About ESR:

Emerging Stock Report is a leading provider of independent investment research for North American companies. Our services include research analysis on emerging growth companies, sector specific research, real-time news and financial data, market commentary and the ESR newsletter. Emerging Stock Report's staff of investment professionals are dedicated to providing the the tools and resources necessary to make important investment decisions. To view our research reports on a complimentary trial basis and take advantage of our other services, visit http://www.emergingstockreport.com and click on the complimentary trial subscription button on our home page, or go directly to our registration page at http://emergingstockreport.com/register.php

About Nutra Pharma Corp.:

Nutra Pharma Corp.(OTCBB:NPHC) is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.

ESR Disclosure:

Emerging Stock Report is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. Emerging Stock Report has not been compensated by any of the above mentioned companies. Please read our report and visit our Web site, http://www.EmergingStockReport.com, for complete risks and disclosures.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Emerging Stock Report

CONTACT: Emerging Stock Report
Dylan Anderson
206-905-9680
info@emergingstockreport.com

Related terms: acquisition, advisor, cancer, clinical, drugs, hiv, investment, market, nervous system, pharmaceuticals, products, property, research, securities, subscription, technology, trial, web